Abstract
Drug efflux proteins are widespread amongst microorganisms, including pathogens. They can contribute to both natural insensitivity to antibiotics and to emerging antibiotic resistance and so are potential targets for the development of new antibacterial drugs. The design of such drugs would be greatly facilitated by knowledge of the structures of these transport proteins, which are poorly understood, because of the difficulties of obtaining crystals of quality. We describe a structural genomics approach for the amplified expression, purification and characterisation of prokaryotic drug efflux proteins of the Major Facilitator Superfamily (MFS) of transport proteins from Helicobacter pylori, Staphylococcus aureus, Escherichia coli, Enterococcus faecalis, Bacillus subtilis, Brucella melitensis, Campylobacter jejuni, Neisseria meningitides and Streptomyces coelicolor. The H. pylori putative drug resistance protein, HP1092, and the S. aureus QacA proteins are used as detailed examples. This strategy is an important step towards reproducible production of transport proteins for the screening of drug binding and for optimisation of crystallisation conditions to enable subsequent structure determination.
Keywords: Membrane transport, transport protein, drug resistance, antibiotic resistance, multidrug resistance, gene expression, protein production, membrane protein
Current Drug Targets
Title: Microbial Drug Efflux Proteins of the Major Facilitator Superfamily
Volume: 7 Issue: 7
Author(s): Martin K. Pos, Peter J.F. Henderson, Roslyn M. Bill, Melissa H. Brown, Nicholas G. Rutherford, John O'Reilly, Ian T. Paulsen, Ronald A. Skurray, Richard B. Herbert, Kate Langton, Karl Walraven, Patrick Butaye, Massoud Saidijam, Scott Morrison, Johan Meuller, Gerda Szakonyi, Kim E. Bettaney, Alison Ward, Sarah L. Palmer, Christopher J. Hoyle, Zhiqiang Xu, Qinghu Ren and Giulia Benedetti
Affiliation:
Keywords: Membrane transport, transport protein, drug resistance, antibiotic resistance, multidrug resistance, gene expression, protein production, membrane protein
Abstract: Drug efflux proteins are widespread amongst microorganisms, including pathogens. They can contribute to both natural insensitivity to antibiotics and to emerging antibiotic resistance and so are potential targets for the development of new antibacterial drugs. The design of such drugs would be greatly facilitated by knowledge of the structures of these transport proteins, which are poorly understood, because of the difficulties of obtaining crystals of quality. We describe a structural genomics approach for the amplified expression, purification and characterisation of prokaryotic drug efflux proteins of the Major Facilitator Superfamily (MFS) of transport proteins from Helicobacter pylori, Staphylococcus aureus, Escherichia coli, Enterococcus faecalis, Bacillus subtilis, Brucella melitensis, Campylobacter jejuni, Neisseria meningitides and Streptomyces coelicolor. The H. pylori putative drug resistance protein, HP1092, and the S. aureus QacA proteins are used as detailed examples. This strategy is an important step towards reproducible production of transport proteins for the screening of drug binding and for optimisation of crystallisation conditions to enable subsequent structure determination.
Export Options
About this article
Cite this article as:
Pos K. Martin, Henderson J.F. Peter, Bill M. Roslyn, Brown H. Melissa, Rutherford G. Nicholas, O'Reilly John, Paulsen T. Ian, Skurray A. Ronald, Herbert B. Richard, Kate Langton , Karl Walraven , Patrick Butaye , Saidijam Massoud, Scott Morrison , Meuller Johan, Szakonyi Gerda, Bettaney E. Kim, Ward Alison, Palmer L. Sarah, Hoyle J. Christopher, Xu Zhiqiang, Ren Qinghu and Benedetti Giulia, Microbial Drug Efflux Proteins of the Major Facilitator Superfamily, Current Drug Targets 2006; 7 (7) . https://dx.doi.org/10.2174/138945006777709575
DOI https://dx.doi.org/10.2174/138945006777709575 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Changes in the Apoptotic and Survival Signaling in Cancer Cells and Their Potential Therapeutic Implications
Current Cancer Drug Targets Inhibiting Cyclin-Dependent Kinase / Cyclin Activity for the Treatment of Cancer and Cardiovascular Disease
Current Pharmaceutical Biotechnology Dietary Pattern for Helicobacter pylori Eradication
The Natural Products Journal Oxidative Stress, Redox Signaling and Cancer Chemoresistance: Putting Together the Pieces of the Puzzle
Current Medicinal Chemistry Metalloproteinases Suppression Driven by the Curcumin Analog DM-1 Modulates Invasion in BRAF-Resistant Melanomas
Anti-Cancer Agents in Medicinal Chemistry The Review of the Synthesis of Bestatin, an Effective Inhibitor of Aminopeptidase N
Mini-Reviews in Organic Chemistry Purinergic Signalling: What is Missing and Needed Next? The Use of Transgenic Mice, Crystallographic Analysis and MicroRNA
CNS & Neurological Disorders - Drug Targets Naturally Occurring Hydroxytyrosol: Synthesis and Anticancer Potential
Current Medicinal Chemistry Identifying and Validating Oncology Therapeutic Targets in the Post- Genomics Era
Current Genomics Nanocarriers Conjugated with Cell Penetrating Peptides: New Trojan Horses by Modern Ulysses
Current Pharmaceutical Biotechnology Food-derived Bioactive Peptides - Opportunities for Designing Future Foods
Current Pharmaceutical Design Importance of Influx and Efflux Systems and Xenobiotic Metabolizing Enzymes in Intratumoral Disposition of Anticancer Agents
Current Cancer Drug Targets The Role of Nuclear Factor-κB in Inflammatory Lung Disease
Inflammation & Allergy - Drug Targets (Discontinued) Graphical Abstracts:
Current Nanoscience [1, 2, 4]-Oxadiazoles: Synthesis and Biological Applications
Mini-Reviews in Medicinal Chemistry Synthesis, Anti-proliferative Evaluation, and Molecular Docking Studies of 3-(alkylthio)-5,6-diaryl-1,2,4-triazines as Tubulin Polymerization Inhibitors
Letters in Drug Design & Discovery Role of CD73 in Disease: Promising Prognostic Indicator and Therapeutic Target
Current Medicinal Chemistry Emerging Roles for Modulation of microRNA Signatures in Cancer Chemoprevention
Current Cancer Drug Targets The Functions of Polo-Like Kinases and their Relevance to Human Disease
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents MALAT1 Promotes Tumorigenesis and Increases Cellular Sensitivity to Herceptin in HER2-positive Breast Cancer
Current Cancer Drug Targets